Comparison of efficacy and adverse events by treatment cycles of nivolumab and ipilimumab in Japanese melanoma patients: A single-center, retrospective study.

J Dermatol · 2025 · PMC11975187 · PMID 40040577

Europe PMC DOI

hedged sentence

0.3310

closest p · 6.6× alpha

0.3310

boldest claim

The sentences

showed a trendp = 0.331not close (p > 0.1)

The ORRs were not significantly different, but the NIVO+IPI ≤2 cycles group showed a trend toward a higher ORR than the NIVO+IPI ≥3 cycles group (25.0% vs 13.8%, p = 0.331) (Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.